

Ibex, an SME based in Israel, brings on the future of cancer diagnostics & prognostics with AI powered pathology for personalization of cancer treatment.

Looking for to join a consortium as a partner on IMI call 23, Topic 4: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence

Ibex in a nutshell

Ibex Medical Analytics develops AI-based cancer diagnostics in pathology, enabling optimization of the full cancer care continuum. We develop algorithms that support cancer diagnostics in pathology labs and prognostic & predictive algorithms for the personalization of cancer treatment. Ibex deployed the first-ever AI-based pathology diagnosis system under the **Galen™ Platform** in a live clinical setting for prostate & breast biopsies, which is providing invaluable field experience in the analysis of real-world clinical data. Furthermore, the Galen Prostate solution has obtained CE-IVD certification, demonstrating unparalleled accuracy during a multi-site clinical study, with the highest AUC reported for cancer detection, 0.997.

We are interested in joining as a partner in an established or forming consortium contributing actively or leading in AI and novel real-world data platform generation, based on our experience in discovering new AI based diagnostic and prognostic markers that improve cancer treatment.

Ibex potential contribution

Our role in a forming consortium could be leading or actively participating in the activities and deliverables under the **Objective 3** of this call, **Leverage the real-world-data gathered by the action to establish an AI-knowledge base and support treatment decisions for prioritized indications**. We are already experienced in similar projects in prostate and breast cancer where we use our core technology for discovering new AI-based diagnostic and prognostic markers from biopsies and other clinical and imaging data that may improve cancer treatment. We could contribute to the **required deliverables** such as, **generation of a decision-support tool** that automatically extracts relevant clinical information specifically from biopsies and integrate with other relevant clinical data. Also Ibex could contribute to the **discovery of new methodology and knowledge** by **applying AI and deep learning**, and combining collected data including clinical data, other imaging data and genetic data, in order to further refine and improve on risk stratification, and subsequently treatment response.

Ibex experience & expertise

Ibex has a strategic partnership with Maccabi Healthcare Services with exclusive access to one of the world's largest and most detailed clinical datasets, with millions of biopsies, pathology reports and EMRs all interconnected. **Technological excellence**: Our R&D team has decades worth of relevant experience from academia, industry and from elite Israeli army units with team members who won multiple Kaggle awards, as well as experts in diagnostics and pharma domains, in addition to clinical expertise and leadership.

IBEX

Our unique approach to AI and multi-disciplinary expertise enables the rapid implementation of our solutions due to a holistic and rounded understanding of the ecosystem, key for success in healthcare.

Ibex solution for prostate biopsies is CE-IVD certified and clinically deployed globally, and for breast biopsies is deployed in Israel (in course of CE-IVD certification). Ibex has been awarded several grants from the **Israel Innovation Authority,** participates in **European consortia** on prostate cancer (ReIMAGINE) and other research projects on **AI markers for drug response.** Ibex has won prizes including **the Innovation Award at MEDinISRAEL 2019,** was selected to be a part of Digital Health London and was featured as one of Nanalyze **7 AI cancer diagnostics startups** digitizing healthcare.

Forming consortia/ coordinators are invited to contact:

Manuela Vecsler, PhD | Scientific & Clinical Affairs Manager
Ibex Medical Analytics
+972-50-7658246 | manuela.vecsler@ibex-ai.com

IBEX › www.ibex-ai.com

https://www.linkedin.com/company/ibexmedicalanalytics

https://twitter.com/IbexMedAx